Cancer screening program extended, expanded for low-income women

What it does

This bill extends federal funding and updates the National Breast and Cervical Cancer Early Detection Program through 2030, reauthorizing two separate cancer-screening initiatives. It expands the program's stated goals to include prevention and disparities reduction, streamlines reporting requirements, and appropriates $235.5 million annually for fiscal years 2026–2030 to support screening, diagnostic services, and navigation support for women seeking breast and cervical cancer detection.

Why we flagged it

The bill's core function is extending and expanding federal funding for an existing cancer-screening program serving low-income women. It is a straightforward reauthorization with modest scope expansion, not a new policy or carve-out.

What the text implies

• Shift from 'follow-up services and support services such as case management' to 'appropriate follow-up services are provided' may narrow the scope of mandated support services, potentially reducing case management availability.
• Reporting frequency changes from annual to every 5 years after initial 2-year report may reduce transparency and oversight of program performance and equity outcomes.
• GAO study due Sept 30, 2027 will assess barriers and trends, but findings come after 2 years of expanded program operation—late for course correction if disparities persist.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill extends and expands a public health program that provides free or low-cost breast and cervical cancer screening and diagnostic services to uninsured and underinsured women. Expanded language on disparities reduction, navigation support, and prevention directly increases access and removes barriers for vulnerable populations.

Who stands to gain

• State and local health departments (program administrators)
• Community health centers and federally qualified health centers (service providers)
• Women's health organizations and cancer advocacy groups (potential contractors for navigation/educat

Named in the bill

National Breast and Cervical Cancer Early Detection Program, Public Health Service Act, Centers for Disease Control and Prevention (implied administrator), Committee on Health, Education, Labor, and Pensions (Senate), Committee on Energy and Commerce (House), Comptroller General of the United States

Where it stands

20 cosponsors: 15 Democrats, 5 Republicans.

• Jul 17, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jul 17, 2025 — Referred to House Committee on Energy and Commerce and Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Referred to the House Committee on Energy and Commerce”
• May 13, 2026 — Markup held in committee · Congress.gov: “Subcommittee Consideration and Mark-up Session Held”
• May 21, 2026 — Reported out of committee · Congress.gov: “Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0”
• Jul 20, 2026 — Passed the House · Congress.gov: “On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required)…”
• Jul 20, 2026 — Floor vote scheduled · Congress.gov: “Mr. Guthrie moved to suspend the rules and pass the bill, as amended”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

5 lobbying clients named this bill on 6 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $3,020,000 in lobbying spend. A filing names 28 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 78% of bills with at least one filing.

Debbie Wasserman Schultz, the sponsor, reported $768,550 in PAC receipts in the 2026 cycle. $3,500 of that came from 1 PAC tied to these lobbying clients.

• American Cancer Society Cancer Action Network Inc — $2,380,000 on 1 filing
• GE Healthcare Technologies Inc. — $350,000 on 1 filing
• The Susan G. Komen Breast Cancer Foundation, Inc. Dba Susan G. Komen — $130,000 on 1 filing
• Hadassah, the Women's Zionist Organization of America, Inc. — $120,000 on 2 filings
• Susan G. Komen — $40,000 on 1 filing

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.